1. Home
  2. WETH vs CDT Comparison

WETH vs CDT Comparison

Compare WETH & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

WETH

Wetouch Technology Inc.

HOLD

Current Price

$1.83

Market Cap

21.1M

Sector

N/A

ML Signal

HOLD

CDT

Conduit Pharmaceuticals Inc.

SELL

Current Price

$3.36

Market Cap

22.1M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
WETH
CDT
Founded
1992
2019
Country
China
United States
Employees
N/A
6
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.1M
22.1M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
WETH
CDT
Price
$1.83
$3.36
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
43.2K
98.0K
Earning Date
04-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
15.38
N/A
EPS
0.60
N/A
Revenue
$45,136,818.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.65
N/A
Revenue Growth
6.76
N/A
52 Week Low
$0.76
$0.37
52 Week High
$3.68
$11.00

Technical Indicators

Market Signals
Indicator
WETH
CDT
Relative Strength Index (RSI) 70.68 50.08
Support Level $1.82 $3.18
Resistance Level $1.85 $4.50
Average True Range (ATR) 0.14 1.10
MACD 0.06 -0.21
Stochastic Oscillator 90.67 11.98

Price Performance

Historical Comparison
WETH
CDT

About WETH Wetouch Technology Inc.

Wetouch Technology Inc is a touch panel supplier focused on R&D, production, and sales of touch screen products. It offers touchscreens for a variety of applications, including GPS/car entertainment panels for the automotive industry, industrial human-machine interface, financial and banking terminals, point of sale, lottery and gaming machines, smart home, robots, and charging stations. The company sells touchscreen products both domestically in China and internationally. The company generates the majority of its revenue from the PRC, followed by the Republic of China and Korea.

About CDT Conduit Pharmaceuticals Inc.

CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. The company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The group is committed to creating shareholder value through licensing, strategic M&A, and positioning the company as a platform for transformative innovation.

Share on Social Networks: